Autopsy report · NCT04104321

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

“Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 157 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Suspended

Phase

Phase 3

Sponsor

Galmed Research and Development, Ltd.

Sponsor type

Industry

Conditions

Nonalcoholic Steatohepatitis (NASH)

Interventions

Aramchol free acid; Placebo

Participants

157

Sites

2

Countries

United States

Trials that died the same way

• Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
  “The study is closed per results from the interim analysis.” (75% match in meaning)
• RCT of Mobile Apps & FitBit v. Usual Care
  “Study is paused for interim analysis.” (70% match in meaning)
• Verapamil vs Steroid to Prevent Keloid Recurrence
  “Objective of study achieved after interim analysis.” (69% match in meaning)
• A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
  “After a positive interim analysis, the decision was made to terminate the study early to allow for participants to enroll into an open label study” (68% match in meaning)
• Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
  “study paused for interim analysis” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.